GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (STU:MAH0) » Definitions » Price-to-Funds-From-Operations

Mereo BioPharma Group (STU:MAH0) Price-to-Funds-From-Operations : (As of Dec. 12, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mereo BioPharma Group Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Mereo BioPharma Group Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).